Saptalis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAPTALIS PHARMS, and when can generic versions of SAPTALIS PHARMS drugs launch?
SAPTALIS PHARMS has sixteen approved drugs.
There is one US patent protecting SAPTALIS PHARMS drugs.
There are five patent family members on SAPTALIS PHARMS drugs in five countries and seventy-two supplementary protection certificates in fifteen countries.
Summary for Saptalis Pharms
| International Patents: | 5 |
| US Patents: | 1 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 16 |
Drugs and US Patents for Saptalis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | VOSOL HC | acetic acid, glacial; hydrocortisone | SOLUTION/DROPS;OTIC | 012770-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Saptalis Pharms | DESOXIMETASONE | desoximetasone | CREAM;TOPICAL | 203787-001 | Jan 6, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Saptalis Pharms | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | SPRAY;TOPICAL | 207094-001 | Dec 7, 2016 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Saptalis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 112020014376 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Try a Trial |
| Canada | 3087789 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Saptalis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | SPC/GB08/040 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
| 1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 3141251 | 301099 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
